PORTAGE, Ind., Dec. 19 /PRNewswire/ -- MonoSol Rx today announced that Alexander Mark Schobel has joined the Company as its President and CEO. Mark is joining MonoSol Rx from Novartis (NYSE: NVS - News) where he held several positions of increasing responsibility with his most recent appointment being Global Head of New Technology and Product Innovation. Mark has over 27 years of industry experience covering the identification, research, development and commercialization of technology and product programs. Concurrent with Mark’s joining, MonoSol Rx is moving its headquarters to New Jersey in order to better serve its pharmaceutical customer base. Production operations will remain in Portage, Indiana.
Prior to Novartis, Mark worked at Pharmaceutical Formulations, Warner- Lambert Company and Block Drug. Mark has a BS in Chemistry from Fairleigh Dickinson University and is a named inventor on 12 patents ranging from diagnostic tests to controlled release systems.
The hiring of a CEO from the pharmaceutical community was planned at the Company’s inception as was the separation of MonoSol Rx as a stand-alone business from MonoSol LLC. The original CEO of MonoSol Rx, P. Scott Bening, will continue as President & CEO of MonoSol LLC, a dynamic and growing business which is the world’s largest manufacturer of Water Soluble Specialty films.
Mark Schobel commented: “MonoSol Rx has a vital IP portfolio and deep competencies in oral film delivery. I am looking forward to working with the Company’s existing customers as well as helping to build new relationships.”
Richard C. Fuisz M.D., a board member and the founder of Fuisz Technologies and Kosmos Pharma, commented: “I have known Mark for several years and he is an extremely bright and accomplished individual. As the Company continues its rapid growth, it has a firm hand at the tiller.”
About MonoSol Rx LLC (http://www.monosolrx.com). MonoSol Rx LLC’s manufacturing facility is located in Portage, Indiana. MonoSol Rx is a leading drug delivery company that uses film as a fast-dissolve oral drug delivery platform. MonoSol Rx previously acquired substantially all of the assets of Kosmos Pharma, including its extensive oral film intellectual property portfolio. MonoSol Rx’s FDTAB® film oral dosage form looks like a postage stamp and dissolves readily on the tongue to deliver drugs to a patient, replacing the use of conventional tablets and capsules. MonoSol Rx
Source: MonoSol Rx LLC
